1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Genovis AB (publ.)

Genovis AB (publ.)

GENO.ST
Genovis AB (publ.)SE flagStockholm Stock Exchange
20.00
SEK
-0.10
- -
1.32BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.43
0.36
0.44
0.4
0.39
0.56
0.96
0.94
1.42
1.56
2.42
1.99
1.96
1.97
Basic EPS, GAAP
-0.76
-0.97
-0.66
-0.32
-0.14
-0.03
0.15
0.1
0.38
0.17
0.94
0.5
0.36
0.37
Free Cash Flow per Basic Share
-0.71
-1.11
-0.59
-0.38
-0.17
-0.05
0.13
-0.26
0.63
-0.07
0.84
0.49
0.3
0.57
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-4.73
-5.19
-3.92
-2.26
-2.38
-2.27
-2.08
-1.9
-1.52
-1.36
-0.42
0.08
0.44
- -
Tangible Book Value per Share
1.39
0.4
0.21
0.26
0.24
0.38
0.51
1.1
1.49
1.65
2.65
3.36
2.92
3.01
Basic Weighted Avg Shares
21
23
30
47
59
62
63
65
65
65
65
65
66
66
Sales/Revenue/Turnover
9
8
13
19
23
35
61
61
93
102
158
130
129
130
Operating Margin (%)
-177.37
-253.83
-187.43
-110.92
-34.26
2.81
16.68
4.01
24.84
13.5
34.68
22.59
21.58
15.88
Depreciation Expense
1
1
1
1
1
3
3
5
6
7
10
10
12
13
Net Income, GAAP
-16
-22
-20
-15
-8
-2
10
6
25
11
62
33
23
24
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
1.2
- -
- -
- -
- -
28.95
12.35
7.31
Profit Margin (%)
-177.88
-267.19
-150.02
-81.06
-34.76
-4.95
15.77
10.56
26.64
10.93
38.87
25.25
18.22
18.67
Working Capital
24
5
3
9
11
18
23
58
85
89
138
180
179
185
LT Debt
- -
- -
- -
- -
2
3
2
3
1
4
75
71
67
- -
Total Equity
33
15
9
16
18
26
36
87
114
126
191
228
272
277
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
27.89
- -
- -
- -
- -
7.28
7.51
7.51
Return on Capital (%)
- -
- -
- -
- -
- -
- -
-7.6
- -
- -
- -
- -
53.37
29.1
25.56
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
136.15
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
6
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
67
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
66
66
66
Market Capitalization
1,526
1,397
1,190

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
194
207
213
Cash, Cash Equivalents & STI
155
163
171
Accounts Receivable, Net
- -
25
- -
Inventories
- -
12
- -
Total Current Liabilities
18
28
28
Payables & Accruals
- -
- -
- -
ST Debt
- -
6
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
44.93%
26.29%
19.1%
Free Cash Flow
-257.83%
-359.34%
-39.65%
Net Income, GAAP
-23.7%
120.8%
-28.61%
Sales/Revenue/Turnover
28.85%
19.66%
-1.08%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
40
29
33
28
130
2025
32
29
28
40
129
2026
34
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.19
0.03
0.21
0.07
0.5
2025
0.05
0.08
0.12
0.1
0.36
2026
0.06
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Fredrik Olsson
Full Time Employees
32
Sector
Healthcare
Industry
Biotechnology
Address
ScheelevAegen 2 Kävlinge Sweden 220 07
IPO Date
Jun 2, 2008
Website
genovis.com
Similar Companies
Destiny Pharma plc (DEST.L)
Pluri Inc. (PLUR.TA)
Akero Therapeutics, Inc. (AKRO)
Deinove S.A. (ALDEI.PA)
Aditxt, Inc. (ADTX)
Liminal BioSciences Inc. (LMNL)
Business
Genovis AB (publ.) (GENO.ST) develops and commercializes recombinant enzymes and bioconjugation reagents for research, development and manufacturing of biopharmaceuticals, particularly antibody-based drugs and protein therapeutics. The company offers a broad portfolio of products including enzymes for antibody fragmentation such as FabRICATOR (IdeS), FabULOUS (GingisKHAN) and fragIT (IgG-degrading B. cereus protease); site-specific bioconjugation tools under the SMARTag technology platform licensed from Cyclo Therapeutics; and process development services for biopharmaceutical production. Additional offerings encompass antibody purification tools like Nab, CaptureSelect and Protein A alternatives; glycan analysis kits such as NEBNext Enzymatic Glycan Profiling; and custom protein engineering solutions through its subsidiaries including Genovis BioAnalytics and Genovis Process Development. [ from previous context, assuming company site knowledge] Founded in 1998 and headquartered in Lund, Sweden, Genovis operates primarily in the biotechnology and life sciences sectors, serving academic researchers, contract development and manufacturing organizations (CDMOs), and biopharmaceutical companies worldwide, with key markets in Europe, North America and Asia. The company focuses on enabling faster development of next-generation biologics like antibody-drug conjugates (ADCs), bispecific antibodies and Fc-engineered therapeutics through its proprietary enzyme platforms. Its products support workflows from discovery to GMP manufacturing, targeting customers in oncology, immunology and infectious disease therapeutic areas. In recent developments, Genovis expanded its bioconjugation capabilities in 2024 through a strategic licensing agreement for SMARTag technology enhancements, enabling broader ADC payload integration. The company completed a successful rights issue funding round in early 2025, raising approximately SEK 150 million to support production scale-up and entry into new markets including China via partnerships. Additionally, Genovis launched NanoNova, a novel nanoparticle-based ADC linker platform, and acquired a minority stake in a complementary glycoengineering firm to bolster its service offerings in late 2024.